Items Tagged ‘ap26113’

October 22nd, 2014

FDA Grants Breakthrough Therapy Designation to AP26113 for ALK-Positive NSCLC

By

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to an investigational agent AP26113 for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non–small cell lung cancer (NSCLC) who are resistant to Xalkori® (crizotinib) This designation is based on results from an ongoing phase I/II trial showing sustained antitumor activity of AP26113 in […]

View full entry

Tags: alk-positive, ap26113, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, Recurrent Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell